Envista Holdings Corporation

NVST

US29415F1049

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
20.39 ^USD	+1.85%		+1.39%	-15.25%

Apr. 26	Morgan Stanley Downgrades Envista Holdings to Equalweight From Overweight, Cuts Price Target to $21 From $33	MT
Apr. 15	Envista Holdings Names Paul Keel as CEO	MT

Envista Holdings Corporation Raises Earnings Guidance for 2021

November 03, 2021 at 04:19 pm EDT

Envista Holdings Corporation raised earnings guidance for 2021. Sales to be $2.475 - $2.500 billion.

Latest news about Envista Holdings Corporation

Morgan Stanley Downgrades Envista Holdings to Equalweight From Overweight, Cuts Price Target to $21 From $33	Apr. 26	MT
Envista Holdings Names Paul Keel as CEO	Apr. 15	MT
Envista Holdings Corporation Announces Chief Executive Officer Changes	Apr. 15	CI
Envista Holdings Corporation Announces Management Changes	Apr. 15	CI
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT
Envista Holdings Starts CEO Succession Process	Feb. 26	MT
Leerink Partners Initiates Envista Holdings at Underperform Rating With $19 Price Target	Feb. 26	MT
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
UBS Adjusts Envista Holdings Price Target to $23 From $26, Maintains Neutral Rating	Feb. 09	MT
Jefferies Downgrades Envista Holdings to Hold From Buy, Adjusts Price Target to $23 From $30	Feb. 09	MT
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
William Blair Downgrades Envista Holdings to Market Perform From Outperform	Feb. 08	MT
Sector Update: Health Care Stocks Steady Premarket Thursday	Feb. 08	MT
Envista Holdings' Q4 Adjusted Earnings Fall, Revenue Rises; Shares Fall Pre-Bell	Feb. 08	MT
Transcript : Envista Holdings Corporation, Q4 2023 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (NVST) ENVISTA HOLDINGS CORPORATION Posts Q4 Revenue $645.6M, vs. Street Est of $638.4M	Feb. 07	MT
Earnings Flash (NVST) ENVISTA HOLDINGS CORPORATION Posts Q4 EPS $0.29, vs. Street Est of $0.34	Feb. 07	MT
Envista Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07	CI
Envista Holdings Corporation Provides Earnings Guidance for the Full Year 2024	Feb. 07	CI
Envista Holdings Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07	CI
Transcript : Envista Holdings Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM	Jan. 08
General Motors US Deliveries Rise 14% in 2023, Led by Electric Vehicle Demand	Jan. 03	MT
Envista Holdings Corporation Appoints Three New Members to Leadership Team	Dec. 14	CI
Needham Starts Envista With Hold Rating	Nov. 16	MT
Transcript : Envista Holdings Corporation Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-16-2023 11:00 AM	Nov. 16

Chart Envista Holdings Corporation

Duration

Period

More charts

Envista Holdings Corporation is a dental products company. The Company provides dental consumables, solutions, technology, and services. It has approximately 30 dental brands, including Nobel Biocare, Ormco and Kerr united. The Company operates through two segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems, and endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents and cements, and infection prevention products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Envista Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

20.02 USD

Average target price

23.18 USD

Spread / Average Target

+15.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ENVISTA HOLDINGS CORPORATION	-15.25%	3.44B
ABBOTT LABORATORIES	-2.31%	185B
MEDTRONIC PLC	-3.20%	105B
BECTON, DICKINSON AND COMPANY	-5.04%	66.59B
DEXCOM, INC.	+0.20%	54.66B
CENCORA, INC.	+17.29%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution